Exploring the antiplatelet activity of serotonin 5-HT2A receptor antagonists bearing 6-fluorobenzo[d]isoxazol-3-yl)propyl) motif– as potential therapeutic agents in the prevention of cardiovascular diseases

@article{Marcinkowska2022ExploringTA,
  title={Exploring the antiplatelet activity of serotonin 5-HT2A receptor antagonists bearing 6-fluorobenzo[d]isoxazol-3-yl)propyl) motif– as potential therapeutic agents in the prevention of cardiovascular diseases},
  author={Monika A Marcinkowska and Monika Kubacka and Agnieszka Zag{\'o}rska and Anna Jaromin and Nikola Fajkis-Zajączkowska and Marcin Kołaczkowski},
  journal={Biomedicine \& Pharmacotherapy},
  year={2022}
}

A Novel Antibody Targeting the Second Extracellular Loop of the Serotonin 5-HT2A Receptor Inhibits Platelet Function

The results indicate that the 5HT2ARAb inhibits 5-HT-enhanced platelet activation in vitro and ex vivo, but has no apparent effects on that which is agonist-induced.

The Advancement of Gas‐Generating Nanoplatforms in Biomedical Fields: Current Frontiers and Future Perspectives

This review comprehensively summarizes the advancements of “state‐of‐the‐art” GGNs in the recent three years, with emphasis on the composition, structure, preparation process, and gas release mechanism of the nanocarriers.

References

SHOWING 1-10 OF 36 REFERENCES

Multifunctional Arylsulfone and Arylsulfonamide-Based Ligands with Prominent Mood-Modulating Activity and Benign Safety Profile, Targeting Neuropsychiatric Symptoms of Dementia

Multifunctional ligands characterized by a nanomolar affinity for clinically relevant targets that are associated with the disease pathology, namely, the 5-HT2A/6/7 and D2 receptors are designed to address the unmet medical need for dementia patients.

Reduction in Hindquarter Vascular Resistance Supports 5-HT7 Receptor Mediated Hypotension

The most prominent regional hemodynamic response to 5-HT7 receptor activation paralleling the fall in MAP is a decrease in skeletal muscle vascular resistance, which is hypothesized to be critical to the cardiovascular effects mediated by the 5- HT7 receptor.

Hemolysis of Human Erythrocytes by Argovit™ AgNPs from Healthy and Diabetic Donors: An In Vitro Study

The hemolytic effect of Argovit™ AgNPs on erythrocytes from one healthy donor and one diabetic donor is evaluated by the hemolysis assay against AgNO3, showing that ArgovIt™ is the least hemolytics compared with the other twenty-two AgNP formulations previously reported.

Inverse Association between Serotonin 2A Receptor Antagonist Medication Use and Mortality in Severe COVID-19 Infection.

Advanced age and medical co-morbidity are strong predictors of mortality in COVID-19 infection. Yet few studies (to date) have specifically addressed risk factors associated with COVID-19 mortality

Management of Dementia-Related Psychosis, Agitation and Aggression: A Review of the Pharmacology and Clinical Effects of Potential Drug Candidates

The recent advances toward the development of therapeutic agents for dementia-related psychosis and agitation/aggression are highlighted and the relationship between the relevant biological targets and their etiology is discussed.

Effects of Selective Serotonin Reuptake Inhibitors on Platelet Function

The epidemiological evidence supports a moderately increased risk of bleeding associated with the use of SSRIs, which may be critically dependent on patient susceptibility and the presence of risk factors.

Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7).

  • R. Glennon
  • Biology
    Journal of medicinal chemistry
  • 2003

Effects of sarpogrelate hydrochloride on platelet aggregation, and its relation to the release of serotonin and P-selectin.

The results suggest that extracellular release of serotonin and P-selectin from platelets was caused by induction of aggregation, and these responses were suppressed by sarpogrelate.